Replies to post #50492 on Biotech Values

[go seek]

and it was so promising in Feb 06... i.e. ANA380

San Diego-based Anadys announced that a small, mid-stage trial of its experimental hepatitis B therapy cut viral loads by more than 99 percent. The Phase II trial included 59 patients who took a dose of ANA380 over a 12-week period. Those taking the three highest doses achieved a reduction of more than 99.9 percent in their viral load. All patients had been previously treated with lamivudine, a standard hep B therapy. Anadys is developing the drug with South Korea's L.G. Life Sciences. A Phase III trial is being prepared.

"These very encouraging Phase II data suggest that ANA380 may very well be the best-in-class among marketed HBV therapies as well as product candidates in development, particularly in difficult-to-treat patients with lamivudine-resistant HBV," said Kleanthis G. Xanthopoulos, Ph.D., president and CEO of Anadys.